While Tenofovir has a dramatically lower inherent chance to go into resistance compared with Adefovir ( almost 30 fold power) , the fundamental consideration is the same. If resistance would develop to the
TDF/LAM combo, Entecavir would still work, limpingly, but secondary resistance could be expected. Somewhat higher expectations of effectiveness/ resistance preventive power can be placed in the use of the FTC/TDF combo a drug already in use for HIV under the name Truvada.